VYZULTA™: A New FDA Approved Glaucoma Medication with Dual Action

On November 2, 2017, the FDA approved VYZULTA™ (latanoprostene bunod 0.024%) for the treatment of glaucoma. This newly available medication treats glaucoma in two distinct ways. One of these methods of protecting the optic nerve has already been available to those...

Pin It on Pinterest